Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories ($CRL) has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus. The CRO expects its new acquisitions to add about 6% to its net sales this year, and the two outfits brought in $87 million in revenue in 2013. More

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.